Spotlight Poster Discussion 4 – Wednesday, December 8, 2021: 5:00 pm – 6:30 pm CT
   
  Brain Metastases: Managing LMD / Targeting HER2
PD4-01 Response according to revised RANO criteria is associated with overall survival in breast cancer patients with leptomeningeal metastasis
Griguolo G, Aldegheri V, Bottosso M, Caumo F, Pouderoux S, Miglietta F, Jacot W, Dieci MV, Darlix A. Guarneri V. University of Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, Padova, Italy; Institut régional du Cancer de Montpellier, Montpellier, France.
PD4-02 Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study
Murthy RK, O'Brien B, Berry DA, Singareeka-Raghavendra A, Gule Monroe M, Johnson J, White J, Childress J, Sanford J, Schwartz-Gomez J, Melisko M, Morikawa A, Ferguson S, de Groot JF, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin NU, Stringer-Reasor E. University of Texas MD Anderson Cancer Center, Houston, TX; University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Dana-Farber Cancer Center, Boston, MA; Baylor College of Medicine, Houston, TX; Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; University of Alabama at Birmingham O’Neal Comprehensive Cancer Center, Birmingham, AL.
PD4-03 Characterization of HER2 amplification in the cerebrospinal fluid of patients with Leptomeningeal Disease in stage IV patients with breast cancer
Dugan M, Fisher D, Sweed N, Blouw B, Mayer J. Biocept, Inc., San Diego, CA; Biocept, Inc., San Diego, CA.
PD4-04 Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)
Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Cameron D, Carey L, Chien AJ, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Dana-Farber Cancer Institute, Boston, MA; University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt University Medical Center, Nashville, TN; Duke Cancer Institute, Durham, NC; Centre Léon Bérard, Lyon, France; University Health Network, Princess Margaret Cancer Centre,, Toronto, ON, Canada; University of Colorado Cancer Center, Aurora, CO; Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of California at San Francisco, San Francisco, CA; Istituto Europeo di Oncologia, IRCCS, University of Milano, Milan, Italy; Yale Cancer Center, New Haven, CT; British Columbia Cancer - Vancouver Centre, Vancouver, BC, Canada; UCLA Medical Center/Jonsson Comprehensive Cancer Center,, Los Angeles, CA; Peter MacCallum Cancer Centre, Melbourne, Australia; German Breast Group, Neu-Isenburg, Guam; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Hospital Universitario Vall D'Hebron,, Barcelona, Spain; Carbone Cancer Center / University of Wisconsin, Madison, WI; Stanford Comprehensive Cancer Institute, Palo Alto, CA; UCLA Medical Center/Jonsson Comprehensive Cancer Center, Los Angeles, CA; Northside Hospital, Sandy Springs, GA; Seagen, Bothell, WA.
PD4-05 Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM)
Kabraji S, Ni J, Sammons S, Van Swearingen AED, Wang Y, Pereslete AM, Hsu L, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JZ, Lin NU. Dana Farber Cancer Institute, Boston, MA; Duke Cancer Institute, Durham, NC; Brigham and Womens Hospital, Boston, MA; UT MD Anderson Cancer Center, Houston, TX.
PD4-06 Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study
Vaz Batista M, Cortez P, Ruiz M, Cejalvo JM, de la Haba J, Garrigós L, Racca F, Servitja S, Blanch S, Teruel I, Pérez-García JM, Gion M, Nave M, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortes J, Braga S. Hospital da Luz, Lisboa, Portugal; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; IOB Institute of Oncology, Hospital Ruber Internacional, Quiron Group, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia, Spain; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital Universitari Dexeus, Barcelona; International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain; IOB Institute of Oncology, Quiron Group, Madrid and, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Instituto Valenciano de Oncología, Valencia; MEDSIR, Barcelona, Spain; Institut Català d'Oncologia Badalona, Badalona, Spain; International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; University Hospital Ramon y Cajal, Madrid, Spain; Hospital Professor Doutor Fernando Fonseca EPE, Lisbon, Portugal; Hospital Arnau de Vilanova; FISABIO; Universidad Católica de Valencia, Valencia; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; International Breast Cancer Center (IBCC), Quironsalud Group; Medica Scientia Innovation Research (MEDSIR); Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital da Luz, Lisbon, Portugal.
PD4-07 Targeting latent residual HER2+ breast cancer brain metastatic cells
Marquez-Palencia M, Malladi S. UT Southwestern Medical Center, Dallas, TX.
PD4-08 Breast cancer clinical subtypes in brain metastases patients from a prospective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM)
López-Tarruella S, Guerrero-Zotano Á, Rodríguez CA, Cruz J, Hernández M, Adrover E, Rodríguez-Lescure Á, Falo C, Martínez P, Miguel A, Andrés R, Antolín S, Chacón JI, Alonso Romero JL, Villanueva Vázquez R, Ballesteros García AI, Galán Gramaje M, Malón Jiménez D, Varela Ferreiro S, Moreno Muñoz D, Campo R, Escudero MJ, Bezares S, Rojo F, Alvarez I. Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense. CIBERONC-ISCIII-.GEICAM Spanish Breast Cancer Group, Madrid, Spain; Fundación Instituto Valenciano de Oncología (FIVO). GEICAM Spanish Breast Cancer Group, Valencia, Spain; Hospital Universitario de Salamanca-IBSAL. GEICAM Spanish Breast Cancer Group, Salamanca, Spain; Hospital Universitario de Canarias. GEICAM Spanish Breast Cancer Group, Santa Cruz de Tenerife, Spain; Complejo Hospitalario Universitario de Gran Canaria Doctor Negrín. GEICAM Spanish Breast Cancer Group, Las Palmas de Gran Canaria, Spain; Hospital General Universitario de Albacete. GEICAM Spanish Breast Cancer Group, Albacete, Spain; Hospital General Universitario de Elche. GEICAM Spanish Breast Cancer Group, Alicante, Spain; ICO Hospitalet. GEICAM Spanish Breast Cancer Group, Barcelona, Spain; Hospital Universitario Basurto. GEICAM Spanish Breast Cancer Group, Bilbao, Spain; ALTHAIA Xarxa asistencial de Manresa. GEICAM Spanish Breast Cancer Group, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa. GEICAM Spanish Breast Cancer Group, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña (CHUAC). GEICAM Spanish Breast Cancer Group, A Coruña, Spain; Hospital Virgen de la Salud. GEICAM Spanish Breast Cancer Group, Toledo, Spain; Hospital Clínico Universitario Virgen de la Arrixaca-IMIB. GEICAM Spanish Breast Cancer Group, Murcia, Spain; Hospital de Sant Joan Despi Moisés Broggi,GEICAM Spanish Breast Cancer Group, Barcelona, Spain; Hospital Universitario de la Princesa. GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Son Llátzer. GEICAM Spanish Breast Cancer Group, Palma de Mallorca, Spain; Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos. GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Universitario Lucus Augusti. GEICAM Spanish Breast Cancer Group, Lugo, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Universitario Fundación Jiménez Díaz. Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense. GEICAM Breast Cancer Group, Madrid, Spain; Unidad de Gestión del Cáncer de Guipúzcoa (Osakidetza-OSI Donostialdea_Onkologikoa)-BioDonostia. GEICAM Spanish Breast Cancer Group, San Sebastián, Spain.
PD4-09 Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors
Giannoudis A, Sokol E, Ramkissoon SH, Bhogal T, McGregor K, Clark A, Razis ED, Bartsch R, Huang RSP, Palmieri C. University of Liverpool, Institute of Systems, Molecular and Integrative Biology, Liverpool, United Kingdom; Foundation Medicine, Inc, Cambridge, MA; Hygeia Hospital, 3rd Oncology Department, Athens, Greece; Medical University of Vienna, Department of Medicine I, Division of Oncology, Vienna, Austria; University of Liverpool, Institute of Systems, Molecular and Integrative Biology and The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom.